Disease Landscape and Forecast Insights

Migraine, which afflicts approximately 73 million people in the major pharmaceutical markets according to Clarivate Epidemiology, is a heterogeneous condition requiring individualized treatment…

The Crohn’s disease (CD) therapy market will grow steadily over the next 10 years as a result of the increasing use of biologics / targeted oral therapies. The well-established TNF-alpha…

The breast cancer treatment landscape is rapidly evolving. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio) combined with endocrine therapy, are established…

Negative symptoms of schizophrenia—often occurring along with positive symptoms—include diminished emotional expression (affective flattening), reduced goal-directed behavior (avolition),…

The hepatocellular carcinoma therapy market is experiencing substantial growth. Angiogenesis inhibitors have played a central role in treating advanced disease, and immunotherapies such as Roche’…

The treatment landscape for paroxysmal nocturnal hemoglobinuria (PNH) has shifted dramatically in the past decade, moving beyond supportive care to transformative complement inhibition therapies…

CDK4/6 inhibitors (Pfizer’s palbociclib, Novartis’s ribociclib, and Eli Lilly’s abemaciclib) combined with endocrine therapy are central to the treatment of metastatic HR-positive / HER2-…

Key benefits and uses Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand whom to position…

Diabetic macular edema (DME), a complication of diabetic retinopathy (DR), develops as a result of persistently elevated blood sugar levels and can lead to vision loss or blindness if left…

The introduction of the immune checkpoint inhibitors Keytruda (Merck & Co.), Opdivo ± Yervoy, and Opdualag (Bristol Myers Squibb), as well as BRAF/MEK inhibitor combinations such as Roche /…

Doublet or triplet chemotherapy alone or in combination with angiogenesis inhibitors remains the cornerstone of treatment for metastatic colorectal cancer. Patients without RAS mutations also…

The chronic obstructive pulmonary disease (COPD) market continues to gradually shift away from LABA/ICS FDCs toward LABA/LAMA FDCs and LABA/LAMA/ICS FDCs, but current and emerging generics are…